Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALB | P02768 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | POLG | P54098 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036650 | 0.85 | TYMP (0.41) | TYMPPOLBCACNA1FLMNAALB | |
| SCHEMBL13036643 | 0.84 | TYMP (0.42) | TYMPPOLBCACNA1FLMNAALB | |
| SCHEMBL837250 | 0.83 | LMNA (0.33) | POLBCACNA1FLMNAALBMAPT | |
| SCHEMBL13036642 | 0.83 | TYMP (0.38) | TYMPPOLBCACNA1FLMNAALB | |
| SCHEMBL12885730 | 0.80 | TYMP (0.38) | TYMPPOLBCACNA1FLMNAALB | |
| SCHEMBL6885492 | 0.79 | POLB (0.53) | TYMPPOLBCACNA1FLMNAALB | |
| SCHEMBL6885494 | 0.79 | POLB (0.53) | TYMPPOLBCACNA1FLMNAALB | |
| SCHEMBL13036664 | 0.78 | TYMP (0.38) | TYMPPOLBCACNA1FLMNAALB | |
| SCHEMBL20527120 | 0.78 | TYMP (0.41) | TYMPPOLBCACNA1FLMNAALB | |
| SCHEMBL21065502 | 0.77 | TYMP (0.41) | TYMPPOLBCACNA1FLMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143396-B2 | 1-[2′, 3′ -dideoxy-3′ C- (hydroxymethyl)—beta-D-erythro-pentofuranosyl] cytosine derivatives as HIV inhibitors | MEDIVIR AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20110112294-A1 | 1-[2', 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112294-A1 | 1-[2', 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | NUDT1, RRM2, TYMP | TYMP 3/4885POLB 16/4885CACNA1F 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.